Emergent BioSolutions announced that it has submitted a Biologics License Application (BLA) to the FDA for Anthrax Immune Globulin Intravenous (Human) [AIGIV] as an intravenous therapy for inhalation anthrax.
AIGIV is a sterile solution of purified human immune globulin G (IgG) containing polyclonal antibodies that targets the anthrax toxins of Bacillus anthracis. It is prepared using plasma collected from healthy, screened donors who have been immunized with BioThrax (Anthrax Vaccine Adsorbed).
Previously in 2008, AIGIV was granted Orphan Drug designation by FDA. AIGIV is being developed as part of a development contract with the Biomedical Advanced Research and Development Authority (BARDA).
For more information call (866) 300-7602 or visit EmergentBioSolutions.